About 1 in 6 U.S. Adults Practice Yoga
Medically reviewed by Drugs.com.
By Ernie Mundell HealthDay Reporter
WEDNESDAY, June 12, 2024 -- Nearly 1 in every 6 U.S. adults have engaged in the ancient practice of yoga over the past year, new government data shows.
In fact, as Americans increasingly turn to alternative or complementary health approaches, "the largest increases [have been] in the practice of yoga," noted researchers Nazik Elgaddal and Julie Weeks. They're with the National Center for Health Statistics (NCHS), which is part of the U.S. Centers for Disease Control and Prevention.
Their new report is based on 2022 data from the ongoing National Health Interview Survey.
According to the data, yoga remains more popular among women (23.3% reporting past-year use) than men (10.3%).
It's also more popular among the young (ages 18 to 44), with 21.3% in that age group saying they practiced yoga, than the middle-aged (14.1%) or those aged 65 or older (8%).
The well-off are also more likely to engage in yoga than less affluent folks. Overall, 23% of people in the survey's highest income bracket said they practiced yoga versus 10.4% of those at the lowest income level.
As to why Americans are engaging in the ages-old Indian practice, about 80% of yoga practitioners cited "restoring overall health," the CDC team found. That was especially true for folks ages 45 to 64.
Meditation is often being performed in conjunction with yoga: Just over 57% of all practitioners said they meditated as part of yoga practice. Lower-income people were more likely to engage in meditation and yoga together compared to better-off folks, the data showed.
Pain relief was another reason cited by many who practiced yoga: About 29% said they engaged in yoga to help "treat or manage pain," the survey found.
Again, lower-income people who engaged in yoga were more likely to say that they used the practice to ease pain compared to higher-income people.
The findings were published June 12 as an NCHS Data Brief.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-06-12 21:15
Read more
- Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism
- About One-Third of Mental Health Facilities Offer Meds for Opioid Addiction
- Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
- Guidelines Address RT for Management of HPV-Linked Oropharyngeal Cancer
- ENDO: Teprotumumab Shows Long-Term Efficacy for Thyroid Eye Disease
- Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of Krazati (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- penginapan di alahan panjang
- nutrition faktory
- doksisiklin
- waist adalah
- kolonoskopi adalah
- obat glimepiride
- antiemetik adalah
- efek samping metformin
- sudut 45 derajat
- plasebo adalah
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions
- qulipta side effects anxiety
- repotrectinib side effects
- ibrance para que sirve
- foods to avoid while taking enbrel
- 反応 速度 鍛える
- baby shampoo eczema
- cdk inhibitor breast cancer
- xulane package insert
- loryna side effects
- keytruda pi
- estarylla vs sprintec
- pros and cons of junel birth control
- tissue plasminogen activator
- jolessa
- ワセリン ベビー パウダー
- tintes para piel morena
- parp 阻害 薬
- デスモイド
- erau ernie
- vasoplex side effects
- rutina de hombros
- merk pre workout
- 湾曲ペニス
- best work out shoes
- ウィニペグ大学
- transparent labs creatine hmb
- nutrition faktory
- メトホルミン 効果発現
- お 風呂 おもちゃ 赤ちゃん
- メトホルミン 副作用